Experimental drug cocktail targets Hard-to-Treat cancers

NCT ID NCT05111561

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This early-stage trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed. The goal is to find a dose that is safe and may shrink or stabilize the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm Neoplasm Metastasis refractory malignant neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID NEOPLASM METASTATIC MALIGNANT SOLID NEOPLASM REFRACTORY MALIGNANT SOLID NEOPLASM TRIPLE-NEGATIVE BREAST CARCINOMA UNRESECTABLE MALIGNANT SOLID NEOPLASM

Contacts and locations

Show contact details

Locations

Boston Medical Center
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02118, United States
Dana-Farber Cancer Institute
SUSPENDED

Boston, Massachusetts, 02215, United States
UT MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Texas Medical Branch
RECRUITING

Galveston, Texas, 77555-0565, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.